Oculis筹集了110万美圆,以推广其神经防护药物,治疗视神经疾病。 Oculis raises $110M to advance its neuroprotective drug for optic nerve diseases.

瑞士一家生物制药公司Oculis Holding AG(Oculis Holding AG)通过销售540万股,每股20.25美元,完成了1亿1 000万美元的超额融资,另有703 703股可选择出售。 Oculis Holding AG, a Swiss biopharmaceutical company, completed an oversubscribed $110 million financing round by selling 5.4 million shares at $20.25 each, with an additional 703,703 shares available under an option. 收益将主要加速Privosegtor的开发,Privosegtor是一个神经保护药物候选者,用于治疗急性光纤内炎和非神经性前天缺血性眼科神经病,同时满足公司的一般需要。 Proceeds will primarily accelerate development of Privosegtor, a neuroprotective drug candidate for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, along with general corporate needs. 预计交易将于2025年11月3日左右结束,涉及新股和国库股,授权股增加到5 720万。 The transaction, expected to close around November 3, 2025, involves new and treasury shares, increasing authorized shares to 57.2 million. J.P.Morgan、Leerink Partners和Pareto 证券公司根据2024年4月以来生效的美国登记声明,领导了这项提议。 J.P. Morgan, Leerink Partners, and Pareto Securities led the offering, conducted under a U.S. registration statement effective since April 2024. Oculis还有另外两个处于晚期的药物候选者,他们正在研制糖尿病脑肿和干眼病的药物。 Oculis also has two other late-stage drug candidates in development for diabetic macular edema and dry eye disease.